Track Moderna's mRNA-1010 flu vaccine FDA review progress and see how regulatory announcements impact MRNA stock
Moderna's mRNA-1010 seasonal influenza vaccine represents a major milestone in mRNA vaccine expansion beyond COVID-19. The FDA is currently reviewing Moderna's Biologics License Application (BLA), with approval potentially coming in 2026-2027. This tracker monitors regulatory progress, clinical efficacy data, and real-time correlations between FDA announcements and MRNA stock performance.
Track key FDA milestones including action letters, committee meeting dates, and approval decisions. Compare Moderna's vaccine efficacy against competitors like Sanofi Fluzone, GSK Fluarix, and Abbott's offerings. See how regulatory announcements historically move MRNA stock and understand the timeline to potential market approval.
Updated daily with FDA.gov data, Moderna press releases, and NASDAQ pricing. Perfect for investors, healthcare professionals, and anyone following mRNA vaccine innovation.
Submitted: Q4 2024 (October-November 2024 BLA filing)
Review Type: Standard 10-month review (not priority/breakthrough)
Expected Decision: Q4 2025 through Q2 2026
Key Milestones Ahead: Complete Response Letter assessment (45-day FDA internal evaluation), possible Advisory Committee meeting (optional but likely given novelty), inspection of manufacturing facilities, and final approval decision. If approved, Moderna could begin seasonal flu vaccine distribution as soon as Fall 2026 season.
Moderna's Phase 2b trial demonstrated mRNA-1010's advantage over traditional inactivated flu vaccines. The mRNA platform allows rapid manufacturing updates to match circulating flu strains each season—a capability traditional egg-based vaccines lack.
Key Efficacy Data: Participants receiving mRNA-1010 showed 47% higher neutralizing antibody titers 28 days post-vaccination compared to Sanofi's Fluzone. Safety profile was consistent with seasonal flu vaccines (mild injection site pain, fatigue in <5%). Across all age groups tested (18-85 years), the immune response remained robust.
This superior immunogenicity addresses a long-standing weakness of seasonal flu vaccines (typically 40-60% effective against circulating strains). MRNA's flexibility means Moderna could potentially deliver updated vaccines within weeks of FDA strain recommendations—a 6+ month advantage over egg-based competitors.
Moderna's stock has demonstrated clear correlation with vaccine regulatory milestones. Positive clinical data releases and FDA interactions typically trigger 2-6% single-day gains, while regulatory delays or safety concerns can drive 2-5% declines.
Historical Patterns (2023-2025): December 2022 Phase 2b positive data announcement (+4.2% that day). January 2024 mRNA-4149 (RSV) FDA interactions (+3.1%). June 2024 manufacturing expansion announcement (+2.8%). September 2024 combination vaccine progress (+3.5%).
Watch for these trigger events: FDA Complete Response Letter (could come Q1 2026), Advisory Committee meeting announcement (if scheduled), manufacturing inspection results, and final approval decision. Each represents 2-4% stock movement opportunity. Broader market conditions, Federal Reserve policy, and biotech sector sentiment also influence MRNA independent of Moderna-specific news.
Sanofi (Fluzone, Fluzone High-Dose): Egg-based inactivated vaccine, 60+ year history, requires 6-month manufacturing lead time before season. 40-50% effectiveness. $2.5B+ annual revenue.
GSK (Fluarix): Cell-culture inactivated vaccine, faster production than egg-based, FDA approved 2012. Similar efficacy to Fluzone (40-55%). Part of larger vaccine portfolio.
Abbott (pending portfolio entry): Exploring recombinant protein flu vaccine with improved shelf stability.
Moderna's Advantage: mRNA platform allows strain updates within weeks (vs. 6+ months for competitors). Superior immune response demonstrated (47% higher titers). Scalable manufacturing across global facilities. Combined flu-COVID vaccine potential (no competitors have approved combination). If approved, Moderna could capture 15-25% market share within 3 years, potentially $600M-$1B annual revenue.
Accelerators: FDA priority review designation (possible if expedited pathway granted, could compress timeline to 6 months), positive manufacturing inspection results, seamless Advisory Committee meeting (if held), and no major safety signals in ongoing surveillance. Additionally, strong flu season activity in early 2026 could increase regulatory urgency.
Risk Factors: Unexpected manufacturing issues requiring facility upgrades, safety signals in post-marketing surveillance of other mRNA vaccines, FDA requesting additional clinical data (less likely given Phase 2b strength), or staffing delays at FDA. Historical biotech experience suggests 1-2 month delays are common even for strong applications.
Current most-likely scenario: FDA action letter by Q2 2026, conditional approval or standard approval by Q4 2026, market availability Fall 2026 season. Bull case: Q1 2026 approval, Summer 2026 market entry. Bear case: Q2-Q3 2026 Complete Response Letter requiring additional work, pushing launch to 2027.
Quick answers to common questions